JP7295576B2 - インスリン産生細胞 - Google Patents

インスリン産生細胞 Download PDF

Info

Publication number
JP7295576B2
JP7295576B2 JP2020549318A JP2020549318A JP7295576B2 JP 7295576 B2 JP7295576 B2 JP 7295576B2 JP 2020549318 A JP2020549318 A JP 2020549318A JP 2020549318 A JP2020549318 A JP 2020549318A JP 7295576 B2 JP7295576 B2 JP 7295576B2
Authority
JP
Japan
Prior art keywords
cells
insulin
group
positive
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020549318A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020059892A5 (cg-RX-API-DMAC7.html
JPWO2020059892A1 (ja
Inventor
亮 伊藤
則子 山添
秀行 日吉
泰佑 持田
光 上野
健介 佐久間
順司 山浦
寛和 松本
太郎 豊田
周平 小長谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orizuru Therapeutics Inc
Original Assignee
Orizuru Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orizuru Therapeutics Inc filed Critical Orizuru Therapeutics Inc
Publication of JPWO2020059892A1 publication Critical patent/JPWO2020059892A1/ja
Publication of JPWO2020059892A5 publication Critical patent/JPWO2020059892A5/ja
Application granted granted Critical
Publication of JP7295576B2 publication Critical patent/JP7295576B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020549318A 2018-09-19 2019-09-18 インスリン産生細胞 Active JP7295576B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018175465 2018-09-19
JP2018175465 2018-09-19
PCT/JP2019/037725 WO2020059892A1 (ja) 2018-09-19 2019-09-18 インスリン産生細胞

Publications (3)

Publication Number Publication Date
JPWO2020059892A1 JPWO2020059892A1 (ja) 2021-08-30
JPWO2020059892A5 JPWO2020059892A5 (cg-RX-API-DMAC7.html) 2022-09-13
JP7295576B2 true JP7295576B2 (ja) 2023-06-21

Family

ID=69887298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020549318A Active JP7295576B2 (ja) 2018-09-19 2019-09-18 インスリン産生細胞

Country Status (14)

Country Link
US (1) US20210353686A1 (cg-RX-API-DMAC7.html)
EP (1) EP3854869A4 (cg-RX-API-DMAC7.html)
JP (1) JP7295576B2 (cg-RX-API-DMAC7.html)
KR (1) KR102892433B1 (cg-RX-API-DMAC7.html)
CN (1) CN112867787B (cg-RX-API-DMAC7.html)
AU (1) AU2019343003B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004815A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113608A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003947A2 (cg-RX-API-DMAC7.html)
IL (1) IL281531B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003147A (cg-RX-API-DMAC7.html)
SG (1) SG11202102748WA (cg-RX-API-DMAC7.html)
TW (1) TWI862513B (cg-RX-API-DMAC7.html)
WO (1) WO2020059892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019169351A1 (en) 2018-03-02 2019-09-06 Semma Therapeutics, Inc. Methods of enhancing stem cell differentiation into beta cells
CN112912490B (zh) * 2018-08-03 2023-12-26 千纸鹤治疗公司 细胞制造方法
EP3833365A4 (en) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
JP7705448B2 (ja) 2020-07-31 2025-07-09 バーテックス ファーマシューティカルズ インコーポレイテッド 膵内分泌細胞の分化
CN116391028A (zh) * 2020-11-20 2023-07-04 千纸鹤治疗公司 促熟剂
TW202246489A (zh) * 2021-02-09 2022-12-01 日商千紙鶴治療公司 成熟化劑
JP2024542041A (ja) 2021-11-01 2024-11-13 バーテックス ファーマシューティカルズ インコーポレイテッド 幹細胞由来の膵臓島分化
IL315122A (en) * 2022-04-25 2024-10-01 Orizuru Therapeutics Inc Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
EP4596675A4 (en) 2022-09-26 2026-03-11 Univ Kyoto PROCESS FOR THE PRODUCTION OF PANCREATIC ENDODERMAL CELLS
EP4753734A1 (en) * 2023-08-02 2026-06-10 Joslin Diabetes Center, Inc. Ribosomal remodeling in diabetes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009528066A (ja) 2006-03-02 2009-08-06 サイセラ,インコーポレイテッド 内分泌前駆細胞、膵臓ホルモン発現細胞及びそれらの製造方法
JP2014501518A (ja) 2010-12-08 2014-01-23 ヴィアサイト,インコーポレイテッド ヒト万能性幹細胞の成長を阻害する薬剤および方法
WO2019208505A1 (ja) 2018-04-23 2019-10-31 国立大学法人京都大学 増殖抑制剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005096873A1 (de) 2004-04-10 2005-10-20 Henkel Kommanditgesellschaft Auf Aktien Lockenwickler
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US7661738B2 (en) 2006-11-28 2010-02-16 Veritainer Corporation Radiation detection unit for mounting a radiation sensor to a container crane
MX348010B (es) 2007-04-07 2017-05-23 Whitehead Inst Biomedical Res Reprogramacion de celulas somaticas.
JP2010528622A (ja) 2007-05-30 2010-08-26 ザ ジェネラル ホスピタル コーポレイション 体細胞から多能性細胞を生成する方法
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009012428A2 (en) 2007-07-18 2009-01-22 Lifescan, Inc. Differentiation of human embryonic stem cells
US9446168B2 (en) 2010-06-07 2016-09-20 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
US9540630B2 (en) 2008-09-17 2017-01-10 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
US20120270890A1 (en) * 2011-04-22 2012-10-25 Cheng-Ho Chung Methods of Pancreatic Beta Cell Regeneration
RU2705001C2 (ru) * 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
IL321825A (en) * 2013-02-06 2025-08-01 Viacyte Inc Cell compositions derived from dedifferentiated reprogrammed cells
WO2015002888A1 (en) * 2013-07-01 2015-01-08 Trustees Of Boston University Dissolvable hydrogel compositions for wound management and methods of use
SG11201700874SA (en) 2014-08-04 2017-03-30 Takeda Pharmaceuticals Co Method for proliferation of pancreatic progenitor cells
CN107250349A (zh) * 2014-12-19 2017-10-13 詹森生物科技公司 多能干细胞的悬浮培养
HK1254740A1 (zh) * 2015-11-30 2019-07-26 Kadimastem Ltd. 分化和纯化胰腺内分泌细胞的方法
MA45329A (fr) * 2016-04-08 2019-02-13 Univ California Production de cellules bêta matures pleinement fonctionnelles à partir de progénitrices pancréatiques humaines
JP6863805B2 (ja) 2017-04-14 2021-04-21 グローリー株式会社 各台装置及び各台装置制御方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009528066A (ja) 2006-03-02 2009-08-06 サイセラ,インコーポレイテッド 内分泌前駆細胞、膵臓ホルモン発現細胞及びそれらの製造方法
JP2014501518A (ja) 2010-12-08 2014-01-23 ヴィアサイト,インコーポレイテッド ヒト万能性幹細胞の成長を阻害する薬剤および方法
WO2019208505A1 (ja) 2018-04-23 2019-10-31 国立大学法人京都大学 増殖抑制剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Diabetologia,2012年,vol. 55, [Suppl1],p. S178-S179,Abstract Number: 420
PAGLIUCA, F.W. et al.,Generation of Functional Human Pancreatic β Cells In Vitro,Cell,2014年10月09日,vol. 159,p. 428-439
REZANIA, Alireza et al.,Enrichment of Human Embryonic Stem Cell-Derived NKX6.1-Expressing Pancreatic Progenitor Cells Accelerates the Maturation of Insulin-Secreting Cells In Vivo,STEM CELL,2013年,vol. 31,p. 2432-2442
REZANIA, Alireza et al.,Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells,Nature Biotechnology,2014年,vol. 32, no. 11,p. 1121-1133, Online Methods,,Supplementary information p. 1-38
RICHARDSON, Thomas, et al.,Alginate Encapsulation of Human Embryonic Stem Cells to Enhance Directed Differentiation to Pancreatic Islet-Like Cells,Tissue Engineering: Part A,2014年,Vol. 20, No. 23 and 24,p. 3198-3211
ROBERT, Thomas et al.,Functional Beta Cell Mass from Device-Encapsulated hESC-Derived Pancreatic Endoderm Achieving Metabolic Control,Stem Cell Reports,2018年03月13日,vol. 10,p. 739-750
YAMASHITA-SUGAHARA, Y. et al.,Scientific Reports,6: 35908 (2016)

Also Published As

Publication number Publication date
AU2019343003A1 (en) 2021-05-13
CN112867787B (zh) 2024-11-22
IL281531B1 (en) 2024-11-01
KR20210060446A (ko) 2021-05-26
BR112021004815A2 (pt) 2021-06-01
IL281531A (en) 2021-05-31
TW202026420A (zh) 2020-07-16
MX2021003147A (es) 2021-05-14
WO2020059892A1 (ja) 2020-03-26
IL281531B2 (en) 2025-03-01
SG11202102748WA (en) 2021-04-29
CA3113608A1 (en) 2020-03-26
EP3854869A4 (en) 2022-09-07
CO2021003947A2 (es) 2021-04-19
CN112867787A (zh) 2021-05-28
TWI862513B (zh) 2024-11-21
US20210353686A1 (en) 2021-11-18
JPWO2020059892A1 (ja) 2021-08-30
KR102892433B1 (ko) 2025-11-27
EP3854869A1 (en) 2021-07-28
AU2019343003B2 (en) 2025-07-17

Similar Documents

Publication Publication Date Title
KR102892433B1 (ko) 인슐린 산생 세포
US20190390169A1 (en) Pancreatic progenitor cell production method
JP6779509B2 (ja) 増殖抑制剤
JP2025000878A (ja) 生体組織様構造体の製造方法
ES3026932T3 (en) Cell production method
RU2829220C2 (ru) Инсулинпродуцирующие клетки
RU2825665C2 (ru) Ингибитор роста
WO2022172960A1 (ja) 成熟化剤
JPWO2017188082A1 (ja) 培地添加剤
WO2023210578A1 (ja) Alk5阻害活性とcdk8/19阻害活性とを有する成熟化剤

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220905

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230309

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230309

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230316

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230328

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230602

R150 Certificate of patent or registration of utility model

Ref document number: 7295576

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250